These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6596102)

  • 1. Effect of anthracyclines and mitoxantrone on oxygen uptake and ATP intracellular concentration in rat heart slices.
    Neri B; Cini-Neri G; D'Alterio M
    Biochem Biophys Res Commun; 1984 Dec; 125(3):954-60. PubMed ID: 6596102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of endogenous respiration in rat heart slices as a measure of mitoxantrone cardiac toxicity.
    Neri B; Cini-Neri G
    Oncology; 1986; 43(4):264-7. PubMed ID: 3725288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects.
    Neri B; Cini-Neri G; Bandinelli M; Pacini P; Bartalucci S; Ciapini A
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):217-21. PubMed ID: 2737789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
    Cini-Neri G; Neri B
    Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical.
    Doroshow JH; Davies KJ
    J Biol Chem; 1986 Mar; 261(7):3068-74. PubMed ID: 3005279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat.
    Cini Neri G; Neri B; Bandinelli M; Del Tacca M; Danesi R; Riccardi R
    Oncology; 1991; 48(4):327-33. PubMed ID: 1891176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin plus lonidamine: in vivo metabolic effects on the rat heart.
    Neri B; Lottini G; Bandinelli E; Cini-Neri G
    Anticancer Drugs; 1991 Aug; 2(4):401-4. PubMed ID: 1797197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfon-m-anisidide, and neocarzinostatin.
    Doroshow JH; Davies KJ
    Biochem Pharmacol; 1983 Oct; 32(19):2935-9. PubMed ID: 6313012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
    Doroshow JH
    Cancer Res; 1983 Feb; 43(2):460-72. PubMed ID: 6293697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of anthracenedione antineoplastic agents on hepatic and cardiac lipid peroxidation.
    Kharasch ED; Novak RF
    J Pharmacol Exp Ther; 1983 Aug; 226(2):500-6. PubMed ID: 6875860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of several anthracyclines on mitochondrial respiration and coenzyme Q10 protection.
    Solaini G; Ronca G; Bertelli A
    Drugs Exp Clin Res; 1985; 11(8):533-7. PubMed ID: 3869924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes.
    Andersson BS; Eksborg S; Vidal RF; Sundberg M; Carlberg M
    Toxicology; 1999 Jul; 135(1):11-20. PubMed ID: 10454220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anthracycline drugs on the element content of cultured embryonic rat cardiomyocytes.
    Djaldetti M; Gilgal R; Sheinberg A; Klein B; Zahavi I
    Arzneimittelforschung; 1991 Nov; 41(11):1173-5. PubMed ID: 1810264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 16. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
    Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
    J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones.
    Buschini A; Poli P; Rossi C
    Mutagenesis; 2003 Jan; 18(1):25-36. PubMed ID: 12473732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
    Alderton PM; Gross J; Green MD
    Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vitro.
    Neri B; Cini-Neri G; Bartalucci S; Bandinelli M
    Anticancer Res; 1986; 6(4):659-62. PubMed ID: 3752946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.